Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04622319 · ClinicalTrials.gov registry record · Phase 3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
A Phase 3 study of HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
- 20
- Study locations
NCT04622319: Active Phase 3 study of HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer, sponsored by Daiichi Sankyo.
NCT04622319 is a Phase 3 study of HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 1,600 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04622319, a Phase 3 study of HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Conditions Studied
Interventions
- DRUG T-DM1
- DRUG DS-8201a
Study Locations (20)
California
- The Oncology Institute of Hope & Innovation - Anaheim
- Kaiser Permanente - Anaheim
- Kaiser Permanente - Baldwin Park
- Kaiser Permanente - Bellflower
- Kaiser Permanente - Fontana
- Orange Coast Blood and Cancer Care - Fountain Valley
- Kaiser Permanente - Harbor City
- Kaiser Permanente - Irvine
- Long Beach Memorial TCI - Long Beach
- Kaiser Permanente - Los Angeles
- Kaiser Permanente - Ontario
- Kaiser Permanente - Panorama City
- Kaiser Permanente - Riverside
- Kaiser Permanente - San Diego
- Kaiser Permanente - San Marcos
- Kaiser Permanente - West Los Angeles
- Kaiser Permanente - Woodland Hills
Florida
- SCRI FCS North- Altamonte - Altamonte Springs
- SCRI FCS South- Bonita - Bonita Springs
- SCRI FCS North- Brandon Cancer Center - Brandon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
What the registry record for NCT04622319 still lists
NCT04622319 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher).
The record links to 2 conditions, with HER2-Positive Primary Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which T-DM1 is the first listed.
NCT04622319 names 20 study sites across 2 states, led by California, Florida.
Frequently Asked Questions
What is clinical trial NCT04622319 about?
NCT04622319 is a clinical study titled "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)". Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of tras...
What is the current status of trial NCT04622319?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,600 participants. The study started on 2020-12-04. Estimated completion is 2030-12-31.
What conditions does trial NCT04622319 study?
This clinical trial studies the following conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.
What interventions are being tested in trial NCT04622319?
The interventions under investigation include: T-DM1 (DRUG), DS-8201a (DRUG).
Who is sponsoring clinical trial NCT04622319?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04622319 being conducted?
This trial has 20 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04622319's enrollment target sits among peer trials
1,600 142nd of 2000 higher than 1,855 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI